home / stock / ngenf / ngenf short
Short Information | NervGen Pharma Corp (OTCMKTS:NGENF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,204,589 |
Total Actual Volume | 1,832,000 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 15 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 60,229 |
Average Short Percentage | 62.46% |
Is there a NGENF Short Squeeze or Breakout about to happen?
See the NGENF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-18-2024 | $2.11 | $2.06 | $2.15 | $2.056 | 54,291 | 32,156 | 59.23% |
07-17-2024 | $2.19 | $2.17 | $2.22 | $2.15 | 23,361 | 9,967 | 42.67% |
07-16-2024 | $2.26 | $2.19 | $2.28 | $2.11 | 39,606 | 31,197 | 78.77% |
07-15-2024 | $2.29 | $2.27 | $2.29 | $2.22 | 37,729 | 24,967 | 66.17% |
07-12-2024 | $2.29 | $2.25 | $2.29 | $2.19 | 75,690 | 65,891 | 87.05% |
07-11-2024 | $2.08 | $2.2065 | $2.25 | $2.03 | 145,520 | 69,044 | 47.45% |
07-10-2024 | $2.07 | $2.055 | $2.112 | $2.01 | 141,504 | 96,517 | 68.21% |
07-09-2024 | $2.15 | $2.0715 | $2.15 | $2.05 | 34,560 | 12,980 | 37.56% |
07-08-2024 | $2.38 | $2.1673 | $2.38 | $2.05 | 90,172 | 51,651 | 57.28% |
07-05-2024 | $2.32 | $2.3585 | $2.42 | $2.31 | 245,462 | 217,959 | 88.8% |
07-03-2024 | $2.23 | $2.3 | $2.3 | $2.02 | 144,795 | 115,713 | 79.92% |
07-02-2024 | $2.05 | $2.04 | $2.15 | $2.04 | 76,184 | 62,226 | 81.68% |
07-01-2024 | $1.945 | $2.16 | $2.16 | $1.945 | 113,804 | 80,303 | 70.56% |
06-28-2024 | $1.97 | $1.98 | $2.1 | $1.85 | 175,222 | 61,667 | 35.19% |
06-27-2024 | $2.105 | $1.97 | $2.24 | $1.95 | 118,244 | 74,254 | 62.8% |
06-26-2024 | $1.83 | $2.1 | $2.1 | $1.83 | 142,089 | 103,341 | 72.73% |
06-25-2024 | $1.8 | $1.83 | $1.92 | $1.7535 | 74,215 | 48,211 | 64.96% |
06-24-2024 | $1.67 | $1.8 | $1.81 | $1.67 | 38,591 | 23,438 | 60.73% |
06-21-2024 | $1.66 | $1.68 | $1.6897 | $1.63 | 20,531 | 12,641 | 61.57% |
06-20-2024 | $1.65 | $1.63 | $1.7 | $1.63 | 40,430 | 10,466 | 25.89% |
News, Short Squeeze, Breakout and More Instantly...
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical ...